MX2015012281A - Proteinas de union a tnf mejoradas. - Google Patents

Proteinas de union a tnf mejoradas.

Info

Publication number
MX2015012281A
MX2015012281A MX2015012281A MX2015012281A MX2015012281A MX 2015012281 A MX2015012281 A MX 2015012281A MX 2015012281 A MX2015012281 A MX 2015012281A MX 2015012281 A MX2015012281 A MX 2015012281A MX 2015012281 A MX2015012281 A MX 2015012281A
Authority
MX
Mexico
Prior art keywords
binding proteins
tnf binding
improved tnf
improved
treatment
Prior art date
Application number
MX2015012281A
Other languages
English (en)
Inventor
Tariq Ghayur
Dominic Ambrosi
Arun B Deora
Subramanya Hegde
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015012281A publication Critical patent/MX2015012281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan proteínas de unión a TNF y métodos de tratamiento que las emplean. También se proporcionan ácidos nucleicos codificantes de las proteínas de unión y los vectores de expresión recombinante y células hospedadoras para preparar dichas proteínas de unión.
MX2015012281A 2013-03-15 2014-03-14 Proteinas de union a tnf mejoradas. MX2015012281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788113P 2013-03-15 2013-03-15
PCT/US2014/027118 WO2014152247A1 (en) 2013-03-15 2014-03-14 Improved tnf binding proteins

Publications (1)

Publication Number Publication Date
MX2015012281A true MX2015012281A (es) 2015-12-16

Family

ID=50489423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012281A MX2015012281A (es) 2013-03-15 2014-03-14 Proteinas de union a tnf mejoradas.

Country Status (10)

Country Link
US (1) US20140294813A1 (es)
EP (1) EP2970458A1 (es)
JP (1) JP2016516041A (es)
CN (1) CN105189550A (es)
AU (1) AU2014239972A1 (es)
BR (1) BR112015019719A2 (es)
CA (1) CA2898676A1 (es)
HK (1) HK1218920A1 (es)
MX (1) MX2015012281A (es)
WO (1) WO2014152247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3464318T3 (pl) * 2016-06-02 2021-11-08 Abbvie Inc. Agonista receptora glukokortykoidowego i jego immunokoniugaty
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN114686450B (zh) * 2020-12-28 2024-04-16 苏州引航生物科技有限公司 经修饰的维生素d羟化酶突变体及其应用
EP4289857A1 (en) 2021-02-04 2023-12-13 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0708585D0 (en) * 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
RU2011127198A (ru) * 2008-12-04 2013-01-10 Эбботт Лэборетриз Иммуноглобулины с двойными вариабельными доменами и их применение
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途

Also Published As

Publication number Publication date
WO2014152247A1 (en) 2014-09-25
CN105189550A (zh) 2015-12-23
WO2014152247A8 (en) 2015-09-03
JP2016516041A (ja) 2016-06-02
AU2014239972A1 (en) 2015-10-08
US20140294813A1 (en) 2014-10-02
WO2014152247A9 (en) 2015-10-22
CA2898676A1 (en) 2014-09-25
BR112015019719A2 (pt) 2017-08-22
HK1218920A1 (zh) 2017-03-17
EP2970458A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MY193497A (en) Anti-myostatin antibodies and methods of use
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12016500388A1 (en) Gitr antigen binding proteins
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201690529A1 (ru) Способы модификации клетки-хозяина
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
WO2015109124A3 (en) Immunomodulatory agents
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
WO2014116846A3 (en) Methods and compositions for modulating an immune response
IL248361B (en) Recombinant host cell for expression of desired proteins
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
TN2016000067A1 (en) Antibodies
HK1251584A1 (zh) 在親和層析中減少宿主細胞蛋白的方法
TN2015000415A1 (en) Anti-cd52 antibodies
MX2015012281A (es) Proteinas de union a tnf mejoradas.
MX356162B (es) Sistema de expresion y secrecion.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
HK1207879A1 (en) An optimized gene sequence encoding for the l1 protein of human papillomavirus type 31 31 l1
HK1251583A1 (zh) 在親和層析中減少宿主細胞蛋白的方法
WO2016160976A3 (en) Monovalent tnf binding proteins
MY195395A (en) Fusion Immunomodulatory Proteins and Methods for Making Same